It is essential that monitor the clinical role of SGLT2 inhibitors in the gout patient population to derive high-quality evidence that could modify future gout management guidelines, similar to the evidence base formed in T2DM, CKD and cardiovascular diseases. The gene discussed is SLC5A2; the disease is chronic kidney disease.